查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930145

全球 GLP-2 类似物市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034 年）

GLP-2 Analogs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

GLP-2 类似物市场成长因子

由于胃肠道疾病（尤其是短肠症候群 (SBS)）的盛行率不断上升，全球 GLP-2 类似物市场正经历稳定成长。 GLP-2 类似物（胰高血糖素样胜肽-2 类似物）是模拟天然 GLP-2 荷尔蒙作用的治疗药物，GLP-2 荷尔蒙在肠道生长、营养吸收和肠道完整性方面发挥重要作用。 这些药物主要用于因肠道功能障碍而依赖肠外营养和补液的短肠症候群（SBS）患者。

根据这份报告，全球GLP-2类似物市场预计在2025年达到12亿美元。预计该市场将在2026年增长至18.3亿美元，并在2034年达到26.5亿美元，在预测期（2026-2034年）内复合年增长率（CAGR）为6.08%。北美地区在全球市场中占领先地位，预计到2025年将占77.11%的市场占有率，这得益于其先进的医疗基础设施、创新疗法的广泛应用以及积极的临床研究活动。 市场驱动因素 GLP-2类似物市场的主要驱动因素是全球短肠症候群（SBS）盛行率的不断上升。短肠症候群 (SBS) 通常由大型胃肠道手术、先天性异常、克隆氏症以及其他导致肠道长度缩短或营养吸收不良的疾病引起。诊断能力的提高和肠道功能障碍患者生存率的提升，扩大了可治疗的患者群体，直接增加了对 GLP-2 类似物疗法的需求。

此外，肠道修復疗法的临床接受度不断提高，以及 GLP-2 类似物已被证实能够减少患者对全肠外营养 (TPN) 的依赖，进一步推动了市场成长。这些疗法透过改善肠道吸收和减少与 TPN 相关的长期併发症，显着提高了患者的生活品质。

市场限制因子

儘管 GLP-2 类似物疗法具有临床益处，但高昂的治疗成本仍然是限制市场成长的主要因素。 GLP-2 类似物疗法需要复杂的生产流程和大量的研发投入。 此外，这些疗法通常需要每日或长期给药，导致患者和医疗保健系统全年承受沉重的经济负担。成本限制阻碍了其广泛应用，尤其是在发展中地区和价格敏感地区，减缓了整体市场扩张。

市场机会

长效GLP-2类似物的开发为市场带来了强劲的成长机会。製药公司正致力于研发每週一次的製剂，以提高患者的依从性并减少每日註射带来的不便。诸如格雷帕鲁肽和阿普拉鲁肽等候选药物旨在提供持续的治疗效果，同时减少给药频率，预计这将对市场成长产生积极影响。

此外，製剂稳定性和药物传递技术的创新有望提高治疗效果，从而扩大GLP-2类似物的未来临床应用范围。

市场挑战

GLP-2类似物市场面临与生物製剂严格的监管要求相关的挑战。 监管机构要求进行广泛的临床试验，以确保药物的长期安全性和有效性，特别关注胃肠道疾病等不良反应和其他潜在风险。这些监管障碍会增加研发成本、延长审批时间，并可能延迟新产品上市，进而抑制市场成长。

市场趋势

影响市场发展的关键趋势之一是，在短肠症候群 (SBS) 的治疗中，治疗方案正从全肠外营养转向基于 GLP-2 的药物。 GLP-2 类似物透过改善肠道功能和减少对侵入性营养支持的依赖，提供了更具针对性、更符合生理的治疗方法。

另一个重要趋势是临床适应症的扩展，不再局限于 SBS（短肠症候群）。目前的研究正在评估 GLP-2 类似物在克隆氏症、溃疡性结肠炎、化疗引起的肠道疾病和类固醇抗药性胃肠道移植物抗宿主疾病的潜在应用，这有望拓展未来的市场机会。

市场区隔分析

依药物类型划分，市场分为特度格鲁肽和其他药物。特度格鲁肽凭藉其已证实的安全性、明确的临床疗效以及获批用于治疗短肠综合征（SBS）的监管审批，占市场主导地位。其他药物（包括正在研发的长效类似物）预计在预测期内将稳定成长。

依给药途径划分，市场分为肠外给药及口服给药。肠外给药占最大占有率，因为大多数已核准的GLP-2类似物都是用于治疗肠道功能障碍患者的注射疗法。然而，由于患者依从性高以及口服胜肽递送系统的进步，口服给药也日益受到关注。

依分销管道划分，由于线上和线下药局的便利性和可及性提高，它们占了较大的市场占有率。 同时，由于住院患者数量庞大，医院药局继续发挥重要作用。

区域展望

北美地区引领全球GLP-2类似物市场，2025年市场规模达12.3亿美元，预计2026年将成长至14.3亿美元。先进疗法的高普及率、完善的医保体係以及积极的研发活动支撑了该地区的市场主导地位。欧洲由于短肠症候群（SBS）盛行率的上升和高昂的医疗保健支出，占了相当大的市场占有率。亚太地区预计在预测期内将实现显着成长，这主要得益于临床研究的拓展以及政府对罕见疾病的扶持政策。拉丁美洲以及中东和非洲地区预计将保持稳定成长，这主要得益于人们对先进疗法的认识不断提高以及获得这些疗法的途径更加便捷。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家短肠症候群盛行率（2025 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等
  • 主要国家监管和报销状况区域

第五章 全球 GLP-2 类似物市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依药物分类
    • 特度格鲁肽
    • 其他
  • 市场分析、洞察与预测：依给药途径分类
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依销售管道分类
    • 医院药房
    • 线上及零售药房
  • 市场分析、洞察与预测：依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美 GLP-2模拟市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲 GLP-2 模拟市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区 GLP-2 模拟市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲 GLP-2 类似物市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲 GLP-2 类似物市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

章节11 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Nestle
    • Takeda Pharmaceutical Company Limited
    • OxThera
    • Zealand Pharma
    • Ironwood
    • Hanmi Pharm Co., Ltd.
    • Jaguar Health
    • Merck KGaA
    • EnteraBio Ltd.
Product Code: FBI113558

Growth Factors of GLP-2 analogs Market

The global GLP-2 analogs market is experiencing steady growth due to the increasing prevalence of gastrointestinal disorders, particularly short bowel syndrome (SBS). GLP-2 analogs (glucagon-like peptide-2 analogs) are therapeutic agents that mimic the action of the naturally occurring GLP-2 hormone, which plays a crucial role in intestinal growth, nutrient absorption, and gut integrity. These drugs are primarily used in patients with SBS who depend on intravenous nutrition and fluids due to intestinal failure.

According to the report, the global GLP-2 analogs market was valued at USD 1.20 billion in 2025. The market is projected to grow to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, registering a CAGR of 6.08% during the forecast period (2026-2034). North America dominated the global market in 2025 with a 77.11% share, supported by advanced healthcare infrastructure, high adoption of innovative therapies, and strong clinical research activity.

Market Drivers

The primary driver of the GLP-2 analogs market is the rising global prevalence of short bowel syndrome. SBS commonly occurs due to extensive gastrointestinal surgeries, congenital defects, Crohn's disease, or other conditions resulting in reduced intestinal length and impaired nutrient absorption. Improved diagnostic capabilities and higher survival rates among intestinal failure patients have expanded the treatable patient population, directly increasing demand for GLP-2 analog therapies.

In addition, increasing clinical awareness of intestinal rehabilitation therapies and the proven ability of GLP-2 analogs to reduce dependence on total parenteral nutrition (TPN) are further fueling market growth. These therapies significantly improve patients' quality of life by enhancing intestinal absorption and decreasing long-term complications associated with TPN.

Market Restraints

Despite their clinical benefits, high treatment costs remain a major restraint for market growth. GLP-2 analog therapies involve complex manufacturing processes and substantial R&D investments. Moreover, these treatments often require daily or long-term administration, leading to a high annual financial burden on patients and healthcare systems. Cost constraints, especially in developing and price-sensitive regions, limit wider adoption and slow overall market expansion.

Market Opportunities

The market presents strong growth opportunities with the development of long-acting GLP-2 analogs. Pharmaceutical companies are increasingly focusing on weekly-dose formulations that improve patient compliance and reduce the inconvenience associated with daily injections. Pipeline candidates such as glepaglutide and apraglutide are designed to provide sustained therapeutic effects with reduced dosing frequency, which is expected to positively influence market growth.

Additionally, innovations in formulation stability and drug delivery technologies are expected to enhance therapeutic efficacy and expand future clinical applications of GLP-2 analogs.

Market Challenges

The GLP-2 analogs market faces challenges related to stringent regulatory requirements for biologic drugs. Regulatory authorities require extensive clinical trials to ensure long-term safety and efficacy, particularly due to concerns related to gastrointestinal adverse effects and other potential risks. These regulatory hurdles increase development costs, extend approval timelines, and may delay the commercialization of new pipeline products, thereby restraining market growth.

Market Trends

A major trend shaping the market is the shift from total parenteral nutrition to GLP-2-based drug therapies for managing short bowel syndrome. GLP-2 analogs offer a more targeted and physiological treatment approach by improving intestinal function and reducing reliance on invasive nutritional support.

Another important trend is the expansion of clinical indications beyond SBS. Ongoing research is evaluating the potential use of GLP-2 analogs in Crohn's disease, ulcerative colitis, chemotherapy-induced enteropathy, and steroid-refractory gastrointestinal graft-versus-host disease, which may broaden future market opportunities.

Segmentation Analysis

By drug type, the market is segmented into teduglutide and others. The teduglutide segment dominates the market due to its proven safety profile, established clinical efficacy, and regulatory approvals for SBS treatment. Other drugs, including long-acting investigational analogs, are expected to grow steadily during the forecast period.

Based on route of administration, the market is divided into parenteral and oral. The parenteral segment holds the largest share, as most approved GLP-2 analogs are injectable therapies used in intestinal failure patients. However, the oral segment is gaining traction due to higher patient compliance and advancements in oral peptide delivery systems.

By distribution channel, online and retail pharmacies account for a significant share due to improved accessibility and convenience, while hospital pharmacies continue to hold an important position owing to high inpatient treatment volumes.

Regional Outlook

North America led the global GLP-2 analogs market in 2025, with a market value of USD 1.23 billion, which increased to USD 1.43 billion in 2026. High adoption of advanced therapies, strong reimbursement frameworks, and robust R&D activities drive regional dominance. Europe holds a significant market share due to rising SBS prevalence and high healthcare spending. The Asia Pacific region is expected to witness substantial growth during the forecast period, supported by expanding clinical research and government initiatives for rare diseases. Latin America and the Middle East & Africa are anticipated to grow steadily, driven by rising awareness and improving access to advanced treatments.

Competitive Landscape

The GLP-2 analogs market is moderately concentrated, with key players such as Takeda Pharmaceutical Company Limited, Zealand Pharma, and Hanmi Pharm Co., Ltd. holding significant market shares. Takeda's strong position is supported by its approved GLP-2 analog teduglutide, extensive global presence, and high R&D investment. Other companies, including Ironwood, Entera Bio, OxThera, and Merck KGaA, are actively advancing pipeline products and expanding clinical research to strengthen their competitive positioning in the global market.

Conclusion

The GLP-2 analogs market is positioned for sustained growth, driven by the rising prevalence of short bowel syndrome (SBS) and increasing clinical adoption of targeted intestinal rehabilitation therapies. Valued at USD 1.20 billion in 2025, the market is projected to expand to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, growing at a CAGR of 6.08% during 2026-2034. The strong dominance of North America, supported by advanced healthcare infrastructure, high treatment adoption, and robust R&D activity, continues to shape the global market landscape.

While high treatment costs and stringent regulatory requirements remain key challenges, ongoing innovation-particularly the development of long-acting GLP-2 analogs and expansion into new clinical indications-offers meaningful growth potential. Established therapies such as teduglutide continue to anchor market demand, while pipeline candidates are expected to enhance patient compliance and broaden therapeutic options. Overall, continued clinical research, regulatory progress, and expanding awareness of SBS management are expected to support steady market expansion through 2034.

Segmentation By Drug

  • Teduglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

By Geography

  • North America (By Drug, Route of Administration, Distribution Channel, and Country/ Sub-region)
    • U.S.
    • Canada
  • Europe (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
  • 4.5. Regolatory and Reimbursement Scenario, By Key Countries/Region

5. Global GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Teduglutide
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online & Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Teduglutide
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online & Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Teduglutide
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online & Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Teduglutide
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online & Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Teduglutide
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online & Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Teduglutide
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online & Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Nestle
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Takeda Pharmaceutical Company Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. OxThera
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Zealand Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ironwood
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Hanmi Pharm Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Jaguar Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. EnteraBio Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 6: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 10: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 14: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 18: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 22: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global GLP-2 Analogs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global GLP-2 Analogs Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global GLP-2 Analogs Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 7: North America GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 8: North America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America GLP-2 Analogs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America GLP-2 Analogs Market Value Share (%), By Country, 2025
  • Figure 14: Europe GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 15: Europe GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 16: Europe GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 23: Asia Pacific GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 24: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 31: Latin America GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 32: Latin America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 39: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 40: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global GLP-2 Analogs Market Share (%), By Company, 2025